Europe Anticoagulant Reversal Drug Market Overview and Growth by 2027

The anticoagulant reversal drug market in Europe is expected to grow from US$ 270.0 million in 2019 to US$ 655.4 million by 2027; it is estimated to grow at a CAGR of 12.4% from 2019 to 2027.

Anticoagulant reversal drugs are used in the management of hemorrhagic stroke to decrease ongoing bleeding and allow tissues to recover. As per the report ‘Burden of Stroke in Europe’ in 2017, there were 1.12 million incident strokes, 9.53 million stroke survivors, 0.46 million deaths, and 7.06 million disability-adjusted life years lost because of stroke in the European Union. Thus, such high prevalence of stroke is likely to demand anticoagulant reversal drugs during the forecast period.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the anticoagulant reversal drugs market. The Europe anticoagulant reversal drugs market is expected to grow at a good CAGR during the forecast period.

Europe Anticoagulant Reversal Drug Market Segmentation      

By Product

• Prothrombin Complex Concentrates
• Vitamin K
• Protamine
• Tranexamic Acid
• Idarucizumab
• AndeXXa

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Country

• Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Companies Mentioned

• Boehringer Ingelheim International GmbH
• Pfizer Inc
• Octapharma AG
• AMAG PHARMACEUTICALS, INC.
• Fresenius Kabi AG
• Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
• CSL Limited
• Grifols, S.A.

Europe Anticoagulant Reversal Drug Report Scope